-
-
-
-
-
-
-
Artiva receives FDA RMAT designation for rheumatoid arthritis therapy
-
-
-
-
-
-
-
Artiva Biotherapeutics, Inc. (ARTV) Reports Q3 Loss of $0.88
-
-
-
-
-
-
-
Artiva Biotherapeutics, Inc. (ARTV) Reports Q1 Loss of $0.83
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Artiva Biotherapeutics (ARTV)
-
-
-
-
-
-
-
Artiva (ARTV) Files for Proposed IPO
479,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


